OGT promotes NRF1-mediated up-regulation of proteasome subunits (209), which may account in part for the intrinsic resistance of CLL cells to the proteasome inhibitor bortezomib and suggesting it may be overcome by inhibiting OGT (210). The gene discussed is OGT; the disease is B-cell chronic lymphocytic leukemia.